Autolus Therapeutics plc (NASDAQ:AUTL) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET

Company Participants

Olivia Manser - Director, Investor Relations

Christian Itin - Chief Executive Officer

Lucinda Crabtree - Chief Financial Officer

Conference Call Participants

Matt Phipps - William Blair

Nick Abbott - Wells Fargo

Mara Goldstein - Mizuho

Gil Blum - Needham

Simon Baker - Redburn

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Autolus Therapeutics First Quarter 2022 Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Olivia Manser, Director of Investor Relations. Please go ahead, ma’am.

Olivia Manser

Thank you and good morning or good afternoon everyone and thank you for joining us to take part in today’s call on the operational highlights and financial results for the first quarter of 2022. I am Olivia Manser, Director of Investor Relations. And with me today are Dr. Christian Itin, our Chief Executive Officer, and Dr. Lucinda Crabtree, our Chief Financial Officer.

Before we begin, I would like to remind you that during today’s call our discussion will contain forward-looking statements. Please make sure you are familiar with our disclaimer, which is on Slide 2 of the presentation. On Slide 3, you will see the agenda for today, which is as follows. Christian will provide an overview of our operational highlights for the first quarter of 2022. Lucinda will then discuss the company’s financial results, before Christian will conclude with upcoming milestones and any other concluding comments. Finally, of course, we will welcome your questions.

Christian Itin

Thank you, Olivia and good morning to you all. Thank you for joining us. It’s my pleasure to review our progress for the first quarter of 2022.

Please move to Slide 4. For those of you who are new to Autolus, and as a fresher for those who know us well, we are building a fully integrated CAR T company. Building on our broad platform of cell programming technologies, we are generating CAR T products that are tailored to the specific tumor setting. Illustrating this approach are obe-cel, with its focus on physiological engagement of leukemic cells, maximizing potency while improving safety and persistence. AUTO4/5 with a unique targeting approach for T-cell lymphomas and AUTO6NG, a CAR T product candidate building on a clinically validated CAR through GD2 and adding programming modules to render the CAR T-cells insensitive to checkpoint and TGF data inhibition, while increasing CAR T-cell persistence. For manufacturing, we are using common platform and process design principles to generate products that are highly active and persisting in patients.